Wei Tan, Xiang Wang, Yudong Sun, Xiaohui Wang, Jin He, Ling Zhong, Xianhong Jiang, Yan Sun, En Tian, Zhuoying Li, Liangping He, Ying Hao, Bin Tang, Wei Hua, Xiangyu Ma, Jurong Yang
BACKGROUND: Left ventricular hypertrophy (LVH) is highly prevalent in haemodialysis (HD) patients and is associated with an increased risk of death. Roxadustat and recombinant human erythropoietin (rHuEPO, abbreviated as EPO) are the main treatment strategies for renal anaemia in HD patients, but it has not been clear whether there is a difference in their effect on LVH. METHODS: In this multi-centre, prospective, randomized trial of 12-month duration, study participants were randomized in a 1:1 ratio to the roxadustat group or the EPO group...
February 11, 2024: Journal of Internal Medicine